

Pathways Task Force Subcommittee: Standard Operating Procedures

Mission Statement: The mission of Value Pathways powered by NCCN™ is to facilitate the delivery of high quality, high value cancer care to our patients through a physician-driven network-supported program utilizing evidence-based medicine.

Pathway Development/Maintenance Process

1. PURPOSE:

- a. The purpose of this document is to outline the stakeholders, processes and expectations for developing and maintaining clinical, evidence-based medicine pathways (Value Pathways powered by NCCN™) that are governed by The US Oncology Network's Pathways Task Force (PTF).

2. DEFINITIONS

- a. Pathways Task Force (PTF)
 - i. The PTF is a sub-committee of the US Oncology Network P&T committee which governs the development and maintenance of The US Oncology Network's Pathways Program: Value Pathways powered by NCCN™.
 - ii. The PTF advises and makes recommendations to the P&T Committee and The US Oncology Network for incorporation of evidence-based, cost-effective treatment via Value Pathways which supports:
 1. The use of clinical trials;
 2. Evidence-based data for specific cancer types based on disease and patient-specific characteristics
 3. Cost effective systemic treatment;
 4. Continuous monitoring and analysis of results and outcomes.
- b. Value Pathways powered by NCCN™
 - i. Joint evidence and value-based treatment guidelines developed and maintained by The US Oncology PTF in collaboration with designated NCCN Clinical Practice Guidelines in Oncology® disease committee members.
 - ii. Value Pathways powered by NCCN are a subset of the NCCN Clinical Practice Guidelines in Oncology.
- c. Technology Platform: Clear Value PlusSM (CVP): the decision support tool that delivers Value Pathways powered by NCCN and NCCN Clinical Practice Guidelines in Oncology content to practices by interfacing with contracted EHRs.

3. PTF COMPOSITION AND APPOINTMENT (APPENDIX A)

- a. Each pathway will have a corresponding Disease Chair who will oversee development and maintenance of said Pathway. Each Disease Chair is a voting member of the PTF.
- b. Voting members of the PTF within The US Oncology Network are appointed by the P&T Committee Chairman, McKesson Specialty Health Chief Medical Officer and the PTF Chairman.

- c. Terms of membership will be reviewed by the PTF Chair and Executive Lead annually
- d. NCCN will appoint up to 3 physician members for each Pathway as voting members to be involved in the review and incorporation of data into Value Pathways development and update. The physicians will be existing members of the NCCN Guideline Panel for the disease.

4. PTF MEETINGS

- a. PTF meetings will take place monthly on the first Thursday of each month, or as determined by the PTF Executive Lead.
- b. Semi-annual P&T meetings may include in-person meetings.

5. DEVELOPMENT/REVIEW PROCESS

- a. Pathway Updates – General Guidelines
 - i. A process for reviewing and updating Pathways will be followed and timed to correspond with implementation of content into technology platforms (EHRs and Clear Value Plus)
 - ii. A Pathway annual review evaluation will be scheduled to correspond with the NCCN Guideline Annual Review
 - iii. Evidence to be considered for Pathways will be reviewed during monthly PTF calls.
 - iv. Each Pathway will be reviewed for updates/changes at least once per year depending on the available evidence. Reviews will include, but are not limited to:
 - 1. Evidence Tables for any regimens to be considered for addition to Pathways
 - 2. Estimate of financial impact to payer and patient
 - a. Medicare reimbursement will correspond to the most recently published Medicare reimbursement rates (quarter/year)
- b. External Pharmacoeconomic Submissions
 - i. External submissions based on pharmacoeconomic data may be accepted for PTF review.
 - 1. All complete submissions will be reviewed and published online in accordance with guidelines from the MSH website (<https://www.mckesson.com/Specialty/Oncology-Pathways/>)
 - ii. Data will be reviewed by the disease subcommittee initially. If data is deemed worth of full PTF review, a summary of PTF discussion and aggregated votes will be included for display on the MSH site along with the original submission documents once P&T voting is complete
 - 1. The final PTF decision is communicated to the submitter within 120 days of a confirmed complete submission

Appendix A: Physician Composition and Appointments 2023

PTF Chairman:

- John Burke, MD – PTF Chairman, CO

Voting Members

- Jay Andersen, MD – Breast Cancer Co-Chair: OR
- David Andorsky, MD – Hematology Chair (MM, Leukemia): CO
- John Burke, MD – Hematology Chair (Lymphoma): CO
- Makenzi Evangelist, MD – Lung Chair: NY
- Mark Johns, MD – GI Chair: OH
- Mabel Mardones, MD – Breast Cancer Co-Chair: CO
- Dhaval Shah, MD – GU Chair: DE
- Matthew Skelton, MD – Generalist: VA
- Paul Thurmes, MD – Melanoma Chair: MN
- Lori Weinberg, MD – Ovarian Chair: MN

Members-at-large (non-voting):

- Les Busby, MD (P&T Chair)
- Marcus Neubauer, MD (Chief Medical Officer)
- Lalan Wilfong, MD (VBC Representative)

Subcommittee Members (non-voting):

- Manoj Bupathi, MD – GU Cancers: CO
- Mika Cline, MD – GI Cancers: TX
- C. Lance Cowey, MD – Melanoma: TX
- Mitul Gandhi, MD – Hematology: VA
- Sandeep Jain, MD – Melanoma: MN
- Mark Kochenderfer, MD – GI Cancers: VA
- Christopher LaFargue, MD – Ovarian Cancer: TX
- Dustin Manders, MD – Ovarian Cancer: TX
- Hossein Maymani, MD – Lung Cancer: CO
- David McCollum, MD – GI Cancers: TX
- Sujatha Nallapareddy, MD – GI Cancers: TX
- Mohit Narang, MD – GU Cancers: MD
- Ruben Saez, MD – Hematology: TX
- Keeran Sampat, MD – GI Cancers: VA
- Ian Schnadig, MD – GU Cancers: OR
- Karen Tedesco, MD – Breast Cancer: NY
- Keith Wells, MD – Melanoma: OR
- Andrew Whiteley, MD – Hematology: TX
- Stephen Wrzesinski, MD – Melanoma: NY
- Jeff Yorio, MD – Melanoma: TX

NCCN Disease Panel Members: 3/disease

Bladder Cancer

- Terrence Friedlander, MD: University of California, San Francisco
- Ronac Mamtani, MD: Abramson Cancer Center / University of Pennsylvania
- Elizabeth Plimack, MD: Fox Chase Cancer Center

Breast Cancer

- Jame Abraham, MD: Case Comprehensive Cancer Center / Cleveland Clinic
- William J. Gradishar, MD: Northwestern University

Chronic Lymphocytic Leukemia

- Farruk T. Awan, MD: UT Southwestern Medical Center
- R. Gregory Bociek, MD: University of Nebraska Medical Center
- William Weirda, MD: MD Anderson Cancer Center

Colon/Rectal/Anal Cancers

- Al B. Benson, MD: Northwestern University
- Wells Messersmith, MD: University of Colorado Cancer Center
- Alan P. Venook, MD: University of California, San Francisco

Kidney Cancer

- Toni Choueiri, MD: Dana-Farber Cancer Institute
- M. Dror Michaelson, MD, PhD: Dana Farber Cancer Institute
- Kathryn Beckermann, MD, PhD: Vanderbilt University

Melanoma

- Mark Albertini, MD: University of Wisconsin Carbone Cancer Center
- Anthony Olszanski, MD: Fox Chase Cancer Center
- Kari Kendra, MD, PhD: The Ohio State University

Multiple Myeloma

- Natalie Callander, MD: University of Wisconsin Carbone Cancer Center
- Caitlin Costello, MD: University of California, San Diego
- Shaji Kumar, MD: Mayo Clinic Cancer Center

Non-Hodgkin Lymphoma

- Thomas Habermann, MD: Mayo Clinic Cancer Center
- Jakub Svoboda, MD: Abramson Cancer Center at the University of Pennsylvania
- Andrew Zelenetz, MD: Memorial Sloane-Kettering Cancer Center

Non-Small Cell Lung Cancer

- David S. Ettinger, MD: Johns Hopkins Medical Institute
- Sandip Patel, MD: University of California, San Diego

Ovarian Cancer

- Ronald Alvarez, MD: Vanderbilt University
- Lainie Martin, MD: University of Pennsylvania

- Theresa Werner, MD: Huntsman Cancer Institute at the University of Utah

Pancreatic Cancer

- Efrat Dotan, MD: Fox Chase Cancer Center
- Noelle LoConte, MD: University of Wisconsin Carbone Cancer Center
- Margaret Tempero, MD: University of California, San Francisco

Prostate Cancer

- Tanya Dorff, MD: City of Hope Comprehensive Cancer Center
- Xin Gao, MD: Dana Farber Cancer Institute
- Joshua Lang, MD: University of Wisconsin Carbone Cancer Center

Small Cell Lung Cancer

- Apar Kishor Ganti, MD: Nebraska Medicine
- Wade Iams, MD: Vanderbilt University

Appendix B: McKesson Clinical Pharmacy Support

Executive Lead: Aimee Ginsburg, PharmD, BCPS

Clinical Pharmacy Coordinators:

- Andrea Dickens, PharmD, BCOP
- Steven Gilmore, PharmD, BCOP
- Victoria Handy, PharmD, BCOP
- Shannon Hough, PharmD, BCOP